centauri therapeutics limited logo

Centauri Therapeutics Limited

Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. Centauri is pursuing anti-bacterial opportunities on its own and immune-oncology opportunities through its joint venture with Horizon Discovery plc, Avvinity Therapeutics.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.centauritherapeutics.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Discovery Park
Sandwich
United Kingdom
Email
Contact Number
+44 1304 728610

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/centauri-therapeutics-limited” connections=”true” suffix=””]

Alphamer technology is based on chemically synthesized molecules redirecting naturally occurring antibodies to selected pathogens to fight infection what the company calls _programmable immunity.Ó One end of a molecule binds a cell-surface target on a pathogen using an aptamer, while the other end presents specific epitopes that attach to the circulating antibodies.

In Jan 2016, Centauri Therapeutics acquired the Alphamer immuno-therapeutics platform technology for drug discovery and development from Altermune Technologies at an undisclosed amount. The purchase included full rights to patents, proprietary compounds, know-how, and collaboration/ license agreements.

In March 2016, Centauri Therapeutics established a virtual joint venture company, Avvinity Therapeutics, with Horizon Discovery. Avvinity combines Centauris Alphamer Technology with the gene editing and oncology expertise of Horizon.

Till Feb 2017, Centauri Therapeutics raised £5.5 Mn in two seed funding rounds from Investors include Animatrix Capital, a regional investment fund, as well as undisclosed private investors.